Gain_Logo_Color.png
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
June 10, 2021 07:30 ET | Gain Therapeutics
BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing...
Gain_Logo_Color.png
Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021 08:00 ET | Gain Therapeutics
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric...
Gain_Logo_Color.png
Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May
May 17, 2021 08:00 ET | Gain Therapeutics
BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric...
Gain_Logo_Color.png
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
May 10, 2021 16:01 ET | Gain Therapeutics
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team ---Signed a multi-target...
Gain_Logo_Color.png
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
May 03, 2021 07:30 ET | Gain Therapeutics
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase ...
Gain_Logo_Color.png
Gain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
April 27, 2021 16:01 ET | Gain Therapeutics
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing...
Gain_Logo_Color.png
Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress
April 22, 2021 08:00 ET | Gain Therapeutics
BETHESDA, Md., April 22, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing...
Gain_Logo_Color.png
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
April 20, 2021 08:00 ET | Gain Therapeutics
Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets ...
Gain_Logo_Color.png
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares
March 25, 2021 17:57 ET | Gain Therapeutics
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full...
Gain_Logo_Color.png
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
March 18, 2021 07:00 ET | Gain Therapeutics
BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of its common stock at a price of...